Oncology
Ryvu Therapeutics publishes research revealing potential drug combination for colorectal cancer
August 1, 2025Medical Communications, Research and Development Oncology, Ryvu Therapeutics, colorectal cancer
Ryvu Therapeutics has published new findings from its ONCO Prime target discovery platform in Scientific Reports. The study reveals a …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
July 30, 2025Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …
Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment
July 30, 2025Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma
Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …
ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development
July 29, 2025Contract Manufacturing, Manufacturing Services, Mergers and Acquisitions, Research and Development AvenCell Therapeutics, CAR-T therapy, Contract Development Manufacturing Organisation, Good Manufacturing Practice, Immunology, Oncology, ViroCell Biologics, autoimmune diseases, blood cancer
ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield retroviral vector supporting the clinical …
Jazz Pharmaceuticals appoints Renée Galá as CEO to lead next phase of growth
July 16, 2025Research and Development CEO, Corporate, Neurology, Oncology, jazz pharmaceuticals, neurology, neuroscience
Jazz Pharmaceuticals has named Renée Galá as its next chief executive officer (CEO), effective 11 August 2025. Galá, currently president …
VIVES Partners contributes to €84m funding for radiopharma company, Nuclidium
July 14, 2025Medical Communications, Research and Development Nuclidium, Oncology, VIVES Funds, VIVES Partners, radiopharmaceuticals, radiotheranostics
VIVES Partners, the managing company of VIVES Funds, has announced that it will contribute to an €84m Series B financing …
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
July 11, 2025Research and Development BioLabs, BioMed X, Cancer, Oncology, Servier, XSeed Labs, antibody therapy, oncology
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, located at the Spartners incubator …
Eppendorf Award for Young European Investigators 2025 awarded to neuroscientist Varun Venkataramani
July 10, 2025Medical Communications, Medical/ Scientific Writing, Research and Development Neurology, Oncology
Varun Venkataramani, of Heidelberg University Hospital, Germany, has been awarded the 2025 Eppendorf Award for Young European Investigators for his …
Duke Street Bio receives FDA fast track designation for brain metastases treatment
July 8, 2025Medical Communications, Research and Development Duke Street Bio, Oncology, US Food and Drug Administration, brain metastases, breast cancer, fast track designation
Duke Street Bio, a biotech company based in London, UK, has announced that the US Food and Drug Administration (FDA) …
Five facts about UV exposure and sun safety
July 7, 2025Medical Communications Dermatology, Five Facts, Oncology, Skin, melanoma, skincare
1We can acclimatise to UV exposure. For example, we’re more likely to burn if there’s a sunny spell earlier in …
FDA grants accelerated approval for advanced non-small cell lung cancer treatment
July 4, 2025Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review
The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …
Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
July 4, 2025Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer
Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …
Biocon Biologics gains EU approval for bone health therapies
July 4, 2025Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …
Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
June 24, 2025Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …
Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology
June 20, 2025Freelancers, Licensing & business development, Research and Development Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer
Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
